Breaking News Instant updates and real-time market news.

IRWD

Ironwood

$14.12

0.03 (0.21%)

08:23
11/06/18
11/06
08:23
11/06/18
08:23

Ironwood expects to complete separation in 1H19

"Ironwood carried operating momentum from the first half of 2018 through the third quarter, driven by 12% LINZESS demand growth and further advancement of our five ongoing clinical programs with linaclotide, IW-3718, olinciguat and praliciguat," said Peter Hecht, CEO of Ironwood. "LINZESS is the branded prescription market leader in its class, driven by our productive investments in marketing, personal promotion and payer access. LINZESS is a growth brand with years of expected patent coverage ahead, and we and Allergan are investing in multiple innovative strategies that we believe represent an opportunity to drive significant growth going forward. We also made progress on our planned separation, which we believe will better position both companies to bring new treatment options to patients and unlock value for shareholders. Following the separation, we expect Ironwood will be a profitable, leading U.S. GI company. We expect the R&D Co. to harness its expertise in sGC pharmacology, developing five sGC stimulators tailored for serious and orphan diseases." In May 2018, Ironwood announced its intent to separate into two independent, publicly traded companies. The separation is expected to be completed in the first half of 2019 and is anticipated to be tax-free to Ironwood shareholders. Following the separation, Ironwood expects to be profitable and to focus on building a leading U.S. GI healthcare company. Ironwood intends to leverage its broad capabilities to advance a strong GI portfolio, including LINZESS - the branded prescription market-leading product in its class - and two potentially highly differentiated, late-stage development products in IW-3718 and MD-7246. R&D Co. expects to harness its deep expertise in cyclic guanosine monophosphate pharmacology to advance an innovative sGC stimulator pipeline focused on the treatment of serious and orphan diseases. At its strategic core are expected to be five novel sGC stimulator programs tailored to the tissues most relevant to the diseases they are designed to treat, including olinciguat, praliciguat, IW-6463, and late-stage discovery programs targeting serious liver and lung diseases.

  • 06

    Nov

  • 12

    Nov

IRWD Ironwood
$14.12

0.03 (0.21%)

10/31/18
WELS
10/31/18
NO CHANGE
Target $18.5
WELS
Outperform
Ironwood price target lowered to $18.50 from $23 at Wells Fargo
Wells Fargo analyst David Maris lowered his price target on Ironwood (IRWD) to $18.50 after the Allergan (AGN) Q3 results lowered expectations for their jointly produced Linzess product. The analyst notes that the management of Ironwood also subsequently confirmed its base case sales growth of low single digits, also lowering his FY19 EPS view to 63c from 69c. Longer term, Maris keeps his Outperform rating, saying the recent share decline should make the board revisit its strategic review and question whether the company is better off being independent.
10/31/18
HCWC
10/31/18
NO CHANGE
Target $12.5
HCWC
Sell
H.C. Wainwright backs Sell rating on Ironwood with Linzess seen disappointing
H.C. Wainwright analyst Raghuram Selvaraju reiterated his Sell rating on shares of Ironwood Pharmaceuticals (IRWD) after partner Allergan (AGN) indicated with its quarterly earnings report that it expects future revenue growth for Linzess to be in the low- to mid-single digits. He also believes that Ironwood's own financials for the third quarter may prove even more disappointing due to the company's history of poor operational expense control, Selvaraju added. He keeps a $12.50 price target on Ironwood shares ahead of its quarterly report, due on November 6.
10/31/18
MZHO
10/31/18
NO CHANGE
Target $23
MZHO
Buy
Ironwood 18% selloff yesterday overdone, says Mizuho
Ironwood Pharmaceuticals (IRWD) sold off 18% yesterday on Allergan's ((AGN) "unexpectedly muted outlook" for Linzess' growth, Mizuho analyst Irina Koffler tells investors in a research note. The analyst views Ironwood as oversold and reiterates a Buy rating on the shares. She did, however, lower her price target for the stock to $23 from $27 on a reduced Linzess forecast and a zero value for the R&D company spin off.
09/17/18
HCWC
09/17/18
NO CHANGE
Target $12.5
HCWC
Sell
H.C. Wainwright reiterates Sell rating on Ironwood despite Fast Track
H.C. Wainwright analyst Raghuram Selvaraju reiterates a Sell rating on Ironwood Pharmaceuticals after the FDA granted mid-stage clinical candidate praliciguat Fast Track Designation for the treatment of patients with heart failure with preserved ejection fraction. The analyst says the Fast Track designation does not change his viewpoint regarding praliciguat, which he believes is a "risky proposition at best." Selvaraju keeps a $12.50 price target for Ironwood shares.

TODAY'S FREE FLY STORIES

FCAU

Fiat Chrysler

$14.75

0.09 (0.61%)

07:30
02/19/19
02/19
07:30
02/19/19
07:30
Downgrade
Fiat Chrysler rating change  »

Fiat Chrysler downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHH

Choice Hotels

$80.53

-1.47 (-1.79%)

07:29
02/19/19
02/19
07:29
02/19/19
07:29
Recommendations
Choice Hotels analyst commentary  »

Choice Hotels reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTX

Aptinyx

$5.64

-0.07 (-1.23%)

07:29
02/19/19
02/19
07:29
02/19/19
07:29
Hot Stocks
Aptinyx doses first patient in Phase 2 NYX-783 study »

Aptinyx announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLXP

PLx Pharma

$5.11

-0.11 (-2.11%)

07:27
02/19/19
02/19
07:27
02/19/19
07:27
Conference/Events
PLx Pharma to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NBRV

Nabriva Therapeutics

$2.08

0.045 (2.22%)

07:27
02/19/19
02/19
07:27
02/19/19
07:27
Hot Stocks
Nabriva Therapeutics announces FDA acceptance of lefamulin NDAs »

Nabriva Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

WORX

SCWorx

$5.74

-0.07 (-1.20%)

07:27
02/19/19
02/19
07:27
02/19/19
07:27
Hot Stocks
SCWorx announces new customer service agreement »

SCWorx has expanded its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARNC

Arconic

$17.56

0.07 (0.40%)

, JPM

JPMorgan

$105.56

3.14 (3.07%)

07:25
02/19/19
02/19
07:25
02/19/19
07:25
Hot Stocks
Arconic announces $700M accelerated share repurchase agreement »

Arconic (ARNC) announced…

ARNC

Arconic

$17.56

0.07 (0.40%)

JPM

JPMorgan

$105.56

3.14 (3.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ICPT

Intercept

$110.77

-0.42 (-0.38%)

07:24
02/19/19
02/19
07:24
02/19/19
07:24
Hot Stocks
Intercept intends to file for OCA regulatory approval in U.S., Europe in 2H19 »

"We are thrilled to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

CNMD

Conmed

$71.94

0.73 (1.03%)

07:24
02/19/19
02/19
07:24
02/19/19
07:24
Upgrade
Conmed rating change  »

Conmed reinstated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 18

    May

ACB

Aurora Cannabis

$7.04

-0.05 (-0.71%)

, TLRY

Tilray

$76.46

-0.2 (-0.26%)

07:23
02/19/19
02/19
07:23
02/19/19
07:23
Recommendations
Aurora Cannabis, Tilray, CV Sciences, Cronos Group, General Cannabis, CannTrust Holdings, Aphria, MediPharm Labs, Canopy Growth, India Globalization Capital analyst commentary  »

Moody's price target…

ACB

Aurora Cannabis

$7.04

-0.05 (-0.71%)

TLRY

Tilray

$76.46

-0.2 (-0.26%)

CVSI

CV Sciences

$0.00

(0.00%)

CRON

Cronos Group

$21.28

0.46 (2.21%)

CANN

General Cannabis

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

APHA

Aphria

$9.58

0.49 (5.39%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

CGC

Canopy Growth

$47.54

1.49 (3.24%)

IGC

India Globalization Capital

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

ICPT

Intercept

$110.77

-0.42 (-0.38%)

07:22
02/19/19
02/19
07:22
02/19/19
07:22
Hot Stocks
Breaking Hot Stocks news story on Intercept »

Intercept jumps 36% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

ICPT

Intercept

$110.77

-0.42 (-0.38%)

07:22
02/19/19
02/19
07:22
02/19/19
07:22
Hot Stocks
Intercept announces results from Phase 3 REGENERATE study »

Intercept announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

NBLX

Noble Midstream

$32.09

-0.04 (-0.12%)

07:21
02/19/19
02/19
07:21
02/19/19
07:21
Earnings
Noble Midstream reports Q4 EPS $1.00, consensus $1.03 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

FCAU

Fiat Chrysler

$14.75

0.09 (0.61%)

07:21
02/19/19
02/19
07:21
02/19/19
07:21
Downgrade
Fiat Chrysler rating change  »

Fiat Chrysler downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

, UPS

UPS

$110.89

-0.91 (-0.81%)

07:20
02/19/19
02/19
07:20
02/19/19
07:20
Downgrade
XPO Logistics, UPS, FedEx, C.H. Robinson, Amazon.com rating change  »

Morgan Stanley downgrades…

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

UPS

UPS

$110.89

-0.91 (-0.81%)

FDX

FedEx

$179.20

-4.74 (-2.58%)

CHRW

C.H. Robinson

$91.43

0.74 (0.82%)

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

CTB

Cooper Tire

$34.04

0.66 (1.98%)

07:19
02/19/19
02/19
07:19
02/19/19
07:19
Hot Stocks
Cooper Tire sees modest unit volume growth compared to 2018 »

Sees improving operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 14

    May

  • 15

    May

  • 16

    May

CTB

Cooper Tire

$34.04

0.66 (1.98%)

07:18
02/19/19
02/19
07:18
02/19/19
07:18
Hot Stocks
Cooper Tire sees Q1 operating profit margin lower than Q1 »

Management expects Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 14

    May

  • 15

    May

  • 16

    May

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

07:17
02/19/19
02/19
07:17
02/19/19
07:17
Recommendations
XPO Logistics analyst commentary  »

Deutsche puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OPTN

Optinose

$7.40

0.23 (3.21%)

07:17
02/19/19
02/19
07:17
02/19/19
07:17
Hot Stocks
Optinose announces four additional Xhance patents from USPTO »

Optinose announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SXT

Sensient

$62.77

0.19 (0.30%)

07:15
02/19/19
02/19
07:15
02/19/19
07:15
Downgrade
Sensient rating change  »

Sensient downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

CRSP

Crispr Therapeutics

$31.62

0.65 (2.10%)

07:15
02/19/19
02/19
07:15
02/19/19
07:15
Hot Stocks
Crispr Therapeutics, StrideBio announce expanded strategic collaboration »

Crispr Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEVA

Ceva

$28.91

1.23 (4.44%)

07:14
02/19/19
02/19
07:14
02/19/19
07:14
Hot Stocks
Ceva announces collaboration to add C-V2X Rel. 14/15 support to the CEVA-XC DSP »

CEVA announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLUG

Plug Power

$1.62

-0.045 (-2.70%)

07:14
02/19/19
02/19
07:14
02/19/19
07:14
Hot Stocks
Plug Power begins production of next gen class 1 material handling equipment »

Plug Power announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTB

Cooper Tire

$34.04

0.66 (1.98%)

07:13
02/19/19
02/19
07:13
02/19/19
07:13
Earnings
Cooper Tire reports Q4 EPS ex-items 66c, consensus 58c »

Reports Q4 revenue $770M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

  • 14

    May

  • 15

    May

  • 16

    May

ARAV

Aravive

$4.95

0.2 (4.21%)

07:13
02/19/19
02/19
07:13
02/19/19
07:13
Hot Stocks
Aravive receives additional $2.6M disbursement from CPRIT for AVB-S6-500 »

Aravive announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.